Lille, France; Cambridge, MA; February 26, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced its cash position as of December 31, 2020 and revenues for 20202.

View original post here:
GENFIT: Revenues and Cash Position as of December 31, 2020

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *